Announcement • Apr 26
Joincare Pharmaceutical Group Industry Co.,Ltd., Annual General Meeting, Jun 01, 2026 Joincare Pharmaceutical Group Industry Co.,Ltd., Annual General Meeting, Jun 01, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Shenzhen, Guangdong China Reported Earnings • Apr 01
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.73 (down from CN¥0.74 in FY 2024). Revenue: CN¥15.2b (down 2.6% from FY 2024). Net income: CN¥1.34b (down 3.7% from FY 2024). Profit margin: 8.8% (down from 8.9% in FY 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 4.8%. Revenue is forecast to grow 8.0% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 4% per year. Announcement • Mar 30
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q1, 2026 Results on Apr 25, 2026 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 Announcement • Dec 26
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report fiscal year 2025 results at 3:00 PM, China Standard Time on Mar 31, 2026 Reported Earnings • Oct 26
Third quarter 2025 earnings released: EPS: CN¥0.17 (vs CN¥0.17 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.17 (down from CN¥0.17 in 3Q 2024). Revenue: CN¥3.58b (down 2.3% from 3Q 2024). Net income: CN¥306.3m (down 8.6% from 3Q 2024). Profit margin: 8.6% (down from 9.1% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 1% per year. Announcement • Sep 24
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q3, 2025 Results on Oct 24, 2025 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025 Reported Earnings • Aug 23
Second quarter 2025 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.20 (up from CN¥0.18 in 2Q 2024). Revenue: CN¥3.81b (down 2.2% from 2Q 2024). Net income: CN¥349.2m (up 3.7% from 2Q 2024). Profit margin: 9.2% (up from 8.6% in 2Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Declared Dividend • Jul 14
Dividend increased to CN¥0.20 Dividend of CN¥0.20 is 11% higher than last year. Ex-date: 18th July 2025 Payment date: 18th July 2025 Dividend yield will be 1.7%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (27% earnings payout ratio) and cash flows (14% cash payout ratio). The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Jun 26
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report First Half, 2025 Results on Aug 22, 2025 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report first half, 2025 results on Aug 22, 2025 Buy Or Sell Opportunity • Jun 11
Now 21% undervalued Over the last 90 days, the stock has risen 4.1% to CN¥11.77. The fair value is estimated to be CN¥14.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.7% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 30% in the next 2 years. Announcement • Apr 25
Joincare Pharmaceutical Group Industry Co.,Ltd., Annual General Meeting, Jun 06, 2025 Joincare Pharmaceutical Group Industry Co.,Ltd., Annual General Meeting, Jun 06, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Shenzhen, Guangdong China Reported Earnings • Apr 08
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.74 (down from CN¥0.76 in FY 2023). Revenue: CN¥15.6b (down 6.2% from FY 2023). Net income: CN¥1.39b (down 3.9% from FY 2023). Profit margin: 8.9% (up from 8.7% in FY 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 7.7%. Earnings per share (EPS) also missed analyst estimates by 8.3%. Revenue is forecast to grow 9.7% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 2% per year. Announcement • Mar 28
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q1, 2025 Results on Apr 24, 2025 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report Q1, 2025 results on Apr 24, 2025 Announcement • Dec 27
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 08, 2025 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 08, 2025 Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.14 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.18 (up from CN¥0.14 in 3Q 2023). Revenue: CN¥3.66b (down 6.8% from 3Q 2023). Net income: CN¥335.1m (up 25% from 3Q 2023). Profit margin: 9.1% (up from 6.8% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has fallen by 1% per year. Announcement • Oct 11
Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380) announces an Equity Buyback for CNY 500 million worth of its shares. Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380) announces a share repurchase program. Under the program, the company will repurchase not more than CNY 500 million worth of its shares. The repurchases will made at maximum price of CNY 15.4 per share. The company would use its own funds or self-raised funds to repurchase the company's shares. The repurchased shares will be used for equity incentives or employee stock ownership plans, to convert company convertible bonds and to protect the company's value and shareholders' rights. The repurchase period will be valid till September 22, 2025. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥11.87, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 9.1% over the past three years. Announcement • Sep 25
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024 Reported Earnings • Aug 24
Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.19 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.18 (down from CN¥0.19 in 2Q 2023). Revenue: CN¥3.89b (down 6.4% from 2Q 2023). Net income: CN¥336.6m (down 4.6% from 2Q 2023). Profit margin: 8.6% (in line with 2Q 2023). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Declared Dividend • Jul 15
Dividend of CN¥0.18 announced Shareholders will receive a dividend of CN¥0.18. Ex-date: 18th July 2024 Payment date: 18th July 2024 Dividend yield will be 1.7%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (24% earnings payout ratio) and cash flows (10% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 44% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Jun 27
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report first half, 2024 results on Aug 23, 2024 Announcement • May 19
Joincare Pharmaceutical Group Industry Co.,Ltd., Annual General Meeting, Jun 07, 2024 Joincare Pharmaceutical Group Industry Co.,Ltd., Annual General Meeting, Jun 07, 2024, at 14:00 China Standard Time. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.24 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.24 (down from CN¥0.24 in 1Q 2023). Revenue: CN¥4.34b (down 4.8% from 1Q 2023). Net income: CN¥439.8m (down 5.0% from 1Q 2023). Profit margin: 10% (in line with 1Q 2023). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Apr 18
Joincare Pharmaceutical Successfully Completes TG-1000 Phase III Study TaiGen Biopharmaceuticals Holdings Limited announced that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to alleviation of all influenza symptoms after TG-1000 treatment was shorter than that of the placebo group, with a statistically significant difference. TG-1000 also possesses great safety profile, and there was no clinically significant safety concerns observed. Furthermore, TaiGen will advance cooperation and development negotiation in Europe, the U.S., and other Asian countries. It is expected that in the second half of the year, Joincare Pharmaceutical will file a new drug application for TG-1000 in mainland China. The primary endpoint of the study, the median time to alleviation of all influence symptoms of TG-1000 group (60.9 hours), was shorter than that of the placebo group (87.9 hours). It shows that TG-1000 effectively shortens the time for influenza symptom alleviation, which is statistically significant (P<0.0001). The secondary endpoints of the study include antiviral efficacy, clinical symptom alleviation, and influenza related complications. Those indicators are still undergoing testing and statistical analysis. The incidence rate of adverse effect (AE) of TG-1000 group is similar to that of placebo group. TG-1000 treatment group possesses favorable safety profile with no death or serious adverse reaction occurred. The phase III trial of TG-1000 is a multi-center, randomized and double-blinded study. The purpose is to evaluate the efficacy and safety of TG-1000 compared with placebo in adult and adolescent patients with uncomplicated acute influenza infection. 752 participants are randomly allocated to TG-1000 treatment group and placebo control group. Consistent with China influenza surveillance data, the majority of patients admitted to the Phase III trial are influenza virus A infected. Reported Earnings • Apr 03
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: CN¥0.76 (down from CN¥0.79 in FY 2022). Revenue: CN¥16.6b (down 2.9% from FY 2022). Net income: CN¥1.44b (down 4.0% from FY 2022). Profit margin: 8.7% (down from 8.8% in FY 2022). The decrease in margin was driven by lower revenue. Products in clinical trials Phase I: 5 Phase II: 1 Phase III: 1 Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.9%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Mar 29
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥12.03, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total loss to shareholders of 1.5% over the past three years. Announcement • Dec 29
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 03, 2024 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report fiscal year 2023 results on Apr 03, 2024 Buying Opportunity • Oct 25
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 10%. The fair value is estimated to be CN¥14.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 26% in 2 years. Earnings is forecast to grow by 41% in the next 2 years. Announcement • Sep 30
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report Q3, 2023 results on Oct 26, 2023 Buying Opportunity • Sep 05
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be CN¥14.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 26% in 2 years. Earnings is forecast to grow by 41% in the next 2 years. Reported Earnings • Aug 24
Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.18 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.18 (up from CN¥0.18 in 2Q 2022). Revenue: CN¥4.16b (up 6.5% from 2Q 2022). Net income: CN¥352.7m (up 3.5% from 2Q 2022). Profit margin: 8.5% (down from 8.7% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. New Risk • Jul 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Announcement • Jun 28
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report First Half, 2023 Results on Aug 24, 2023 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report first half, 2023 results on Aug 24, 2023 Reported Earnings • Apr 12
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.79 (up from CN¥0.69 in FY 2021). Revenue: CN¥17.1b (up 7.8% from FY 2021). Net income: CN¥1.50b (up 13% from FY 2021). Profit margin: 8.8% (up from 8.4% in FY 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) also missed analyst estimates by 2.2%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Dec 15
Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380) commences an Equity Buyback for CNY 600 million worth of its shares, under the authorization approved on November 18, 2022. Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380) commences share repurchases on December 14, 2022, under the program mandated by the shareholders in the Extraordinary General Meeting held on November 18, 2022. As per the mandate, the company is authorized to repurchase its own shares for a total of CNY 600 million. The shares will be purchased at a price not exceeding CNY 16 per share. The repurchased shares will be used to reduce the registered capital. The program will be funded from company's own funds or self-raised funds. The program will be valid till November 17, 2023. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (5 non-independent directors). Independent Director Liguo Cui was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.16 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.17 (up from CN¥0.16 in 3Q 2021). Revenue: CN¥4.45b (up 8.5% from 3Q 2021). Net income: CN¥325.3m (up 1.2% from 3Q 2021). Profit margin: 7.3% (down from 7.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥12.06, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 28% over the past three years. Reported Earnings • Aug 11
Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.18 (up from CN¥0.16 in 2Q 2021). Revenue: CN¥3.91b (up 5.9% from 2Q 2021). Net income: CN¥340.7m (up 6.3% from 2Q 2021). Profit margin: 8.7% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 12%, compared to a 23% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (5 non-independent directors). Independent Director Liguo Cui was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 31
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: CN¥0.69 (up from CN¥0.57 in FY 2020). Revenue: CN¥15.9b (up 18% from FY 2020). Net income: CN¥1.33b (up 19% from FY 2020). Profit margin: 8.4% (up from 8.3% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 10%, compared to a 24% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 11% per year. Reported Earnings • Oct 27
Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥4.10b (up 13% from 3Q 2020). Net income: CN¥321.3m (up 28% from 3Q 2020). Profit margin: 7.8% (up from 6.9% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 15% per year. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.20 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥3.69b (up 12% from 2Q 2020). Net income: CN¥320.5m (down 19% from 2Q 2020). Profit margin: 8.7% (down from 12% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥16.72, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 25x in the Pharmaceuticals industry in China. Total returns to shareholders of 72% over the past three years. Reported Earnings • Apr 24
First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.14 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥4.14b (up 30% from 1Q 2020). Net income: CN¥366.9m (up 31% from 1Q 2020). Profit margin: 8.9% (up from 8.8% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥0.57 (vs CN¥0.46 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥13.5b (up 13% from FY 2019). Net income: CN¥1.12b (up 25% from FY 2019). Profit margin: 8.3% (up from 7.5% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Announcement • Mar 09
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report fiscal year 2020 results on Mar 31, 2021 Is New 90 Day High Low • Jan 28
New 90-day low: CN¥12.67 The company is down 16% from its price of CN¥15.06 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥15.44 per share. Is New 90 Day High Low • Dec 24
New 90-day low: CN¥13.96 The company is down 19% from its price of CN¥17.25 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥15.44 per share. Is New 90 Day High Low • Nov 10
New 90-day low: CN¥14.59 The company is down 20% from its price of CN¥18.32 on 12 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥13.28 per share. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥1.04b, up 25% from the prior year. Total revenue was CN¥12.8b over the last 12 months, up 7.9% from the prior year. Is New 90 Day High Low • Oct 23
New 90-day low: CN¥16.46 The company is down 15% from its price of CN¥19.41 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥11.34 per share. Announcement • Jul 17
Joincare Pharmaceutical Group Industry Co.,Ltd. announced that it expects to receive CNY 2.1727605 billion in funding from Hillhouse Capital Management, Ltd. Joincare Pharmaceutical Group Industry Co.,Ltd. (SHSE:600380) announced that it has entered into agreement to issue no more than 169,350,000 shares at issue price of CNY 12.83 per share for an aggregate gross proceeds of CNY 2,172,760,500 on July 12, 2020. The transaction will include participation from new investor, Hillhouse China Value Fund, L.P., a fund managed by Hillhouse Capital Management, Ltd. to acquire 8% stake in the company. The shares have a lock up period of 18 months. The transaction has been reviewed and approved at the 29th meeting of the seventh board of directors and the twenty-fourth meeting of the seventh supervisory committee. The transaction still need to be approved by the company’s shareholders’ meeting and the China Securities Regulatory Commission. Announcement • Jul 10
Joincare Pharmaceutical Group Industry Co.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020 Joincare Pharmaceutical Group Industry Co.,Ltd. announced that they will report first half, 2020 results on Aug 28, 2020 
